BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 29248198)

  • 21. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
    Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
    Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
    Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
    Stasenko M; Plegue M; Sciallis AP; McLean K
    Int J Gynecol Cancer; 2015 Feb; 25(2):222-8. PubMed ID: 25500503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.
    Huang Q; Chu C; Tang J; Dai Z
    J Cancer; 2020; 11(18):5353-5358. PubMed ID: 32742481
    [No Abstract]   [Full Text] [Related]  

  • 29. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
    Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
    Baumann KH; du Bois A; Meier W; Rau J; Wimberger P; Sehouli J; Kurzeder C; Hilpert F; Hasenburg A; Canzler U; Hanker LC; Hillemanns P; Richter B; Wollschlaeger K; Dewitz T; Bauerschlag D; Wagner U
    Ann Oncol; 2012 Sep; 23(9):2265-2271. PubMed ID: 22377563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
    Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
    JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
    Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
    J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety of apatinib for the treatment of gastric cancer.
    Geng R; Song L; Li J; Zhao L
    Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
    J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
    Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
    Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
    Bodnar L; Górnas M; Szczylik C
    Gynecol Oncol; 2011 Oct; 123(1):33-6. PubMed ID: 21723597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.
    Song Z; Lou G; Wang Y; Yang Z; Wang W; Ji Y; Chen S; Xu C; Hu X; Zhang Y
    BMC Med; 2022 May; 20(1):154. PubMed ID: 35534877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.